Physician profile
Max Salas
NPI 1528088812
$916.34
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $229.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $384.54 | 2019-2020 | |
| Abbvie INC. | $152.38 | 2019-2020 | |
| Ibsa Pharma INC. | $43.27 | 2019 | |
| Pfizer INC. | $39.92 | 2019 | |
| Dexcom, INC. | $34.35 | 2019 | |
| Arbor Pharmaceuticals, INC. | $33.62 | 2019 | |
| Insulet Corporation | $32.47 | 2019 | |
| Medtronic Minimed, INC. | $30.00 | 2019 | |
| Lilly USA, LLC | $28.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.66 | 2019-2020 | |
| Sandoz INC. | $26.69 | 2019-2020 | |
| Abbott Laboratories | $22.77 | 2020 | |
| Tandem Diabetes Care, INC. | $18.62 | 2020 | |
| Senseonics, Incorporated | $15.00 | 2019 | |
| Endo Pharmaceuticals INC. | $13.67 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $13.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Salas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.